Macro­Gen­ics in­ves­ti­gates three pa­tient deaths in Phase 2 prostate can­cer drug tri­al

Macro­Gen­ics re­port­ed on Thurs­day af­ter­noon that three pa­tients died in a mid-stage tri­al of its an­ti­body-drug con­ju­gate for prostate can­cer. Two par­tic­i­pants died due to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER